Essure
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Essure
| |
| Background | |
| B.C. type | Sterilization |
| First use | 2002 |
| Failure rates (first year, after occlusion) | |
| Perfect use | 0.2% |
| Typical use | ?% |
| Usage | |
| Duration effect | Permanent |
| Reversibility | No |
| User reminders | Additional methods until 3 month check by hysterosalpingogram |
| Clinic review | None |
| Advantages and Disadvantages | |
| STD protection | No |
| Benefits | Permanent contraception |
Essure is a permanent sterilization procedure for women developed by Conceptus Inc and approved for use in the United States on November 4, 2002.[1]
Contents |
Procedure and assessment
Micro-inserts are placed into the fallopian tubes by a catheter passed from the vagina through the cervix and uterus. Once in place, the device is designed to elicit tissue growth (scarring) in and around the micro-insert to form over a period of 3 months an occlusion or blockage in the fallopian tubes; the tissue barrier formed prevents sperm from reaching an egg.
Unlike other forms of tubal ligation, no general anaesthetic nor incision through the abdomen is required. Somewhat similar to male vasectomy procedures, initially additional forms of birth control must be continued to prevent pregnancy until the method's effectiveness can be confirmed. For the Essure method, 3 months after insertion a physician performs a special type of x-ray test called a hysterosalpingogram to confirm that the fallopian tubes are completely blocked and the patient can rely on the Essure micro-inserts for birth control. Occlusion is observed to have occurred in 96.5% of patients at 3 months with the remainder occluded by 6 months.[1]
The reported insertional failure rates are "failure to place 2 micro-inserts in the first procedure (5%), initial tubal patency (3.5%), expulsion (2.2%), perforation (1.8%), or other unsatisfactory device location (0.6%)."[1] Following successful insertion and occlusional response, the Essure procedure is 99.80% effective based on 4 years of follow-up.[1] The Essure procedure has been demonstrated in a small portion of the women undergoing clinical studies to be 99.74% effective based on 5 years of follow-up. Five year follow-up of all patients in clinical trials is ongoing.
Cautions and warnings
The micro-inserts do not prevent the transmission of sexually transmitted diseases. The procedure takes about 35 minutes for a trained physician to perform and can be performed in a physician's office. General anesthesia is not required. Unlike many temporary methods of birth control, the Essure micro-inserts do not contain or release hormones.
The micro-inserts being made from polyester fibers, nickel-titanium and stainless steel are safe to use with MRI equipment.[1]
Risks
- Perforation, expulsion, or other unsatisfactory location of the micro-insert
- Pregnancy and increased risk of ectopic pregnancy
- Risks associated with anesthesia
- Pain, cramping, vaginal bleeding, menstrual pattern changes
- Nausea/vomiting, or fainting
- Vasovagal response
Notes
External links
Birth control | |
|---|---|
| Comparison: | Comparison of birth control methods |
| Behavioral: | Avoiding vaginal intercourse: Anal sex, Oral sex, Non-penetrative sex, Masturbation, Abstinence Including vaginal intercourse: Fertility awareness, Rhythm Method, Withdrawal, Breastfeeding infertility |
| Barrier: | Condom, Female condom, Diaphragm, Cervical cap, Lea's Shield |
| Spermicide: | Contraceptive sponge |
| Hormonal: | Combined: Combined oral contraceptive pill ('the Pill'), Contraceptive patch, NuvaRing, Combined injectable contraceptive Progestogen only: Progestogen only pill ('minipill'), Depo-Provera, Norplant/Jadelle, Implanon |
| Anti-estrogen: | Ormeloxifene (a.k.a. Centchroman) |
| Intra-uterine: | IUD (copper or progestogen), IUS (progestogen) |
| Post-intercourse: | Contraception: Emergency contraception (pills or copper IUD) Abortion: Surgical abortion, Medical abortion (RU-486/abortion pill) |
| Sterilization: | Male: Vasectomy Female: Tubal ligation, Essure |
 | This medical treatment article is a stub. You can help WikiDoc by expanding it. |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
